New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
What you need to know about GLP-1s, and how Omada can help
Learn MoreMedication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Read Resource
Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe
Read Article
Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”
Read Article
On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!
Watch Video
Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.
Read Article
Omada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.
Read Article
Omada’s Clinical Advisory Board demonstrates its commitment to rigorous clinical evaluation and helps underscore the impact of its behavior change programs
Read Article
This analysis showed that across diverse sociodemographic populations, Omada cardiometabolic members experienced improvements in depression and anxiety symptoms.
Read Article
This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order
Read Article
Real-world data analysis shows Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data
Read Article
As the healthcare industry innovates to maximize the GLP-1 experience for patients, there appears to be an important factor that’s arguably under-discussed: loneliness.
Read Article
Omada Insights Lab surveyed and interviewed Omada members with a history of GLP-1 use to learn more about their unique needs and experiences.
Read Resource
Survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals; respondents want to lose an average of 22% more weight.
Read Article
Cardiovascular disease (CVD) remains the leading cause of death among women, yet it is often misdiagnosed and/or undertreated. Join the discussion on the need for more focus on women's heart health.
Watch Video
New consumer data indicates that sustaining weight loss and overall well-being requires intervention beyond the GLP-1
Read Resource
What you need to know about GLP-1s, and how Omada can help
Learn MoreReturn on Health Framework for Realizing the Value of Virtual Care
Read Resource
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
This insightful webinar delves into the expanding role of GLP-1 medications in treating a wide range of chronic conditions beyond diabetes and obesity.
Watch Video
New board members provide deep clinical and commercial experience.
Read Article
Loading More...
